Quarterly ResultAug 7, 2026, 07:08 AM
Purple Biotech Q2 2026 Net Income $0.4M; IM1240 Clinical Entry in 2027
AI Summary
Purple Biotech reported a net income of $0.4 million for the second quarter of 2026, a significant improvement from a net loss of $1.1 million in the prior year, primarily due to a non-cash gain from warrant revaluation. The company's operating loss slightly increased to $1.3 million. Purple Biotech also announced positive preclinical data for its lead candidate, IM1240, at EACR 2026, validating its anti-tumor activity and favorable safety profile, with plans to enter clinical studies in 2027. The company held $6.1 million in cash as of June 30, 2026, providing a cash runway through mid-2027.
Key Highlights
- IM1240 tri-specific antibody is aimed at entering clinical studies in 2027.
- Total cash position was $6.1 million as of June 30, 2026.
- Cash runway is expected through mid-2027 based on current management estimates.
- Net income was $0.4 million for Q2 2026, compared to a net loss of $1.1 million in Q2 2025.
- Operating loss increased to $1.3 million for Q2 2026 from $1.2 million in Q2 2025.
- Research and Development Expenses rose to $0.7 million in Q2 2026 from $0.6 million in Q2 2025.
- New preclinical data for IM1240 presented at EACR 2026 validated its differentiated profile.
- IM1240 demonstrated an 8-fold longer half-life and 16-fold greater systemic exposure.
Price Impact
More from PPBT